何氏眼科(301103)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301103 何氏眼科

已收盘 12-17 15:00:00

{"stockData":{"symbol":"301103","market":"SZ","secType":"STK","nameCN":"何氏眼科","latestPrice":19.3,"timestamp":1765954989000,"preClose":19.15,"halted":0,"volume":1314230,"delay":0,"changeRate":0.0078,"floatShares":122000000,"shares":158000000,"eps":0.0673,"marketStatus":"已收盘","change":0.15,"latestTime":"12-17 15:00:00","open":19.1,"high":19.39,"low":18.94,"amount":25145400,"amplitude":0.0235,"askPrice":19.3,"askSize":296,"bidPrice":19.28,"bidSize":24,"shortable":0,"etf":0,"ttmEps":0.0673,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766021400000},"marketStatusCode":5,"adr":0,"adjPreClose":19.15,"symbolType":"stock","openAndCloseTimeList":[[1765935000000,1765942200000],[1765947600000,1765954800000]],"highLimit":21.07,"lowLimit":17.24,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":158026471,"isCdr":false,"pbRate":1.58,"roa":"--","peRate":286.775632,"roe":"2.87%","epsLYR":-0.1734,"committee":-0.297134,"marketValue":3050000000,"turnoverRate":0.0108,"status":0,"floatMarketCap":2348000000},"requestUrl":"/m/hq/s/301103","defaultTab":"news","newsList":[{"id":"2590513677","title":"何氏眼科：公司在各期定期报告中会披露对应时点的股东信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2590513677","media":"证券日报 ","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590513677?lang=zh_cn&edition=full","pubTime":"2025-12-11 19:34","pubTimestamp":1765452840,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月11日，何氏眼科在互动平台回答投资者提问时表示，为保证所有投资者公平地获取公司的信息，公司在各期定期报告中会披露对应时点的股东信息。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-11/doc-inhamthc8026918.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-11/doc-inhamthc8026918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2590745582","title":"何氏眼科：整合智能算法辅助诊断系统","url":"https://stock-news.laohu8.com/highlight/detail?id=2590745582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590745582?lang=zh_cn&edition=full","pubTime":"2025-12-10 20:51","pubTimestamp":1765371109,"startTime":"0","endTime":"0","summary":"何氏眼科回复：尊敬的投资者您好，公司在智能化系统眼科应用方面，整合了智能算法辅助诊断系统，建设眼科专科智能影像云平台，开发多模态数据融合决策系统，并生成3D眼健康数字孪生模型。此外何氏眼科“光明小屋”以眼科智能设备为入口，结合线上和线下的眼科诊疗系统，通过先进的智能诊断，发现眼部疾病和慢性疾病，打造数字智能技术赋能基层眼健康管理的数字场景。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000037911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2590372250","title":"何氏眼科：何星儒将依法合规推进市值管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2590372250","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590372250?lang=zh_cn&edition=full","pubTime":"2025-12-10 11:36","pubTimestamp":1765337784,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科(301103)12月09日在投资者关系平台上答复投资者关心的问题。投资者提问：请问何星儒何总新官上任，有改变公司上市以来一直处于股价破发的计划吗？何氏眼科回复：尊敬的投资者您好，公司股价受多重因素综合影响，何星儒先生作为新任总经理将全面负责公司日常经营管理事务，致力于提升公司业绩与内在价值，并将根据市场情况和监管要求，依法合规推进市值管理工作。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000013994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2589338541","title":"何氏眼科：公司高度重视股东利益","url":"https://stock-news.laohu8.com/highlight/detail?id=2589338541","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589338541?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:00","pubTimestamp":1765180828,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科12月08日在投资者关系平台上答复投资者关心的问题。关于股东福利的建议，公司高度重视股东利益，会考虑通过多种方式回馈股东，包括但不限于提供公司产品和服务的体验机会，以彰显公司实力、提升品牌形象，同时为股东创造实际价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800013888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2589626813","title":"何氏眼科（301103）披露2025年限制性股票激励计划首次授予结果，12月5日股价上涨0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589626813","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589626813?lang=zh_cn&edition=full","pubTime":"2025-12-05 22:31","pubTimestamp":1764945089,"startTime":"0","endTime":"0","summary":"截至2025年12月5日收盘，何氏眼科报收于20.06元，较前一交易日上涨0.91%，最新总市值为31.7亿元。该股当日开盘19.88元，最高20.1元，最低19.63元，成交额达2547.83万元，换手率为0.81%。同日，公司发布公告称，已于2025年12月5日向240名核心管理人员及核心骨干首次授予510.00万股第二类限制性股票，授予价格为13.00元/股。本激励计划有效期最长不超过60个月，首次授予部分分三年归属，归属比例分别为30%、30%、40%。本次授予不会导致公司股权分布不符合上市条件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500040906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2588401350","title":"何氏眼科：精准医疗与抗衰老已有技术储备和布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2588401350","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588401350?lang=zh_cn&edition=full","pubTime":"2025-12-03 15:27","pubTimestamp":1764746838,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科12月03日在投资者关系平台上答复投资者关心的问题。精准医疗方面，公司下属沈阳何氏眼科医院开设了遗传门诊，开展遗传眼病基因检测、高度近视风险筛查等服务，形成基因治疗全生命周期防控体系。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300018058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2588013323","title":"何氏眼科：公司不排除投资AI眼镜企业的可能性","url":"https://stock-news.laohu8.com/highlight/detail?id=2588013323","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588013323?lang=zh_cn&edition=full","pubTime":"2025-12-03 15:21","pubTimestamp":1764746482,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科12月03日在投资者关系平台上答复投资者关心的问题。关于您提及的领域，公司不排除此类投资的可能性，但具体的投资决策需要根据市场情况和公司战略规划来定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300018011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2588018071","title":"何氏眼科：部分门店引入雷鸟智能眼镜销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2588018071","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588018071?lang=zh_cn&edition=full","pubTime":"2025-12-03 15:18","pubTimestamp":1764746304,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科12月03日在投资者关系平台上答复投资者关心的问题。该合作系基于市场需求的常规业务布局，对公司财务状况及经营成果未构成重大影响。未来，若双方合作涉及重大事项达到信息披露标准，公司将严格按照监管要求及时履行信息披露义务，敬请投资者理性投资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300017981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2586471939","title":"何氏眼科（301103）披露2025年度持续督导定期现场检查报告，11月25日股价上涨1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586471939","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586471939?lang=zh_cn&edition=full","pubTime":"2025-11-25 22:39","pubTimestamp":1764081545,"startTime":"0","endTime":"0","summary":"截至2025年11月25日收盘，何氏眼科报收于20.84元，较前一交易日上涨1.21%，最新总市值为32.93亿元。该股当日开盘20.69元，最高21.0元，最低20.6元，成交额达3093.74万元，换手率为0.94%。公告显示，中原证券对何氏眼科2025年度持续督导进行了现场检查，检查期间为2025年11月11日至12日。检查内容涵盖公司治理、内部控制、信息披露、募集资金使用、业绩情况、承诺履行等方面。部分募投项目因市场环境变化调整实施进度，个别项目终止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500039891.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2584949371","title":"何氏眼科：坚持聚焦主业稳健经营","url":"https://stock-news.laohu8.com/highlight/detail?id=2584949371","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584949371?lang=zh_cn&edition=full","pubTime":"2025-11-19 20:48","pubTimestamp":1763556490,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科11月18日在投资者关系平台上答复投资者关心的问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900037082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2581560727","title":"何氏眼科：已累计回购股份2,722,719股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581560727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581560727?lang=zh_cn&edition=full","pubTime":"2025-11-05 20:51","pubTimestamp":1762347076,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科11月04日在投资者关系平台上答复投资者关心的问题。我是公司长期小股东，十分看好公司布局再生医疗！强烈建议启动股份回购！何氏眼科回复：尊敬的投资者您好，您的建议已收到，截止目前公司已累计回购股份2,722,719股。如有新一轮股份回购计划，公司将严格按照《上市公司股份回购规则》及相关法律法规要求，及时履行审议程序并对外披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500038613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2579104681","title":"何氏眼科（301103）2025年三季报简析：净利润同比增长232.18%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2579104681","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579104681?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:56","pubTimestamp":1761864972,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期何氏眼科发布2025年三季报。截至本报告期末，公司营业总收入8.55亿元，同比下降1.11%，归母净利润5439.53万元，同比上升232.18%。按单季度数据看，第三季度营业总收入2.95亿元，同比上升5.37%，第三季度归母净利润1007.07万元，同比上升230.99%。本报告期何氏眼科盈利能力上升，毛利率同比增幅2.21%，净利率同比增幅414.26%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100010332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103"],"gpt_icon":0},{"id":"2579972407","title":"图解何氏眼科三季报：第三季度单季净利润同比增长230.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579972407","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579972407?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:14","pubTimestamp":1761736495,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科2025年三季报显示，前三季度公司主营收入8.55亿元，同比下降1.11%；归母净利润5439.53万元，同比上升232.18%；扣非净利润4242.87万元，同比上升186.89%；其中2025年第三季度，公司单季度主营收入2.95亿元，同比上升5.37%；单季度归母净利润1007.07万元，同比上升230.99%；单季度扣非净利润518.71万元，同比上升154.22%；负债率15.26%，投资收益973.97万元，财务费用87.07万元，毛利率41.83%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900040093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103"],"gpt_icon":0},{"id":"2578316690","title":"何氏眼科：通过“主业+基金孵化”打造创新生态","url":"https://stock-news.laohu8.com/highlight/detail?id=2578316690","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578316690?lang=zh_cn&edition=full","pubTime":"2025-10-27 15:39","pubTimestamp":1761550746,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科10月27日在投资者关系平台上答复投资者关心的问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700015888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2577753216","title":"股市必读：何氏眼科（301103）10月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2577753216","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577753216?lang=zh_cn&edition=full","pubTime":"2025-10-24 05:42","pubTimestamp":1761255734,"startTime":"0","endTime":"0","summary":"截至2025年10月23日收盘，何氏眼科报收于21.15元，上涨0.67%，换手率0.78%，成交量1.24万手，成交额2605.98万元。董秘最新回复投资者： 贵公司及相关关联方是否在脑机接口方向有所布局？后续如有需要披露的信息，公司将依照信息披露的相关法规履行披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400004394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2577025363","title":"何氏眼科：积极探索AI与AR技术在眼科医疗中的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2577025363","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577025363?lang=zh_cn&edition=full","pubTime":"2025-10-23 20:52","pubTimestamp":1761223954,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科10月23日在投资者关系平台上答复投资者关心的问题。目前公司及公司的关联方沈阳何氏眼产业集团有限公司已与部分行业领先的硬件供应商及科研机构展开接洽，积极探索联合研发、投资孵化等合作模式，该事项对公司当前主营业务开展或业绩未造成重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300035875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0},{"id":"2577782508","title":"10月21日何氏眼科发布公告，股东减持32.18万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2577782508","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577782508?lang=zh_cn&edition=full","pubTime":"2025-10-21 18:01","pubTimestamp":1761040877,"startTime":"0","endTime":"0","summary":"证券之星消息，10月21日何氏眼科发布公告《何氏眼科:关于持股5%以上股东减持计划实施完成的公告》，其股东先进制造产业投资基金(有限合伙)于2025年7月23日至2025年9月8日间合计减持32.18万股，占公司目前总股本的0.2036%，变动期间该股股价下跌3.35%，截止9月8日收盘报22.21元。股东增减持详情见下表：根据何氏眼科2025年中报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100029899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2575068942","title":"何氏眼科：收购日本医道医疗株式会社","url":"https://stock-news.laohu8.com/highlight/detail?id=2575068942","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575068942?lang=zh_cn&edition=full","pubTime":"2025-10-15 15:33","pubTimestamp":1760513587,"startTime":"0","endTime":"0","summary":"证券之星消息，何氏眼科10月15日在投资者关系平台上答复投资者关心的问题。此外，公司本次收购日本医道医疗株式会社专注于再生医疗技术的研究与应用，主营业务涵盖了药品研究、开发及商业化等多个领域，涉及再生医疗领域中对于干细胞、多种植物分泌的外泌体的利用，从分子、细胞、个体、数理层面进行分析，旨在以衰老、炎症疾病、癌症为靶向的分子靶向药物的开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101500019259.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","159891","301103"],"gpt_icon":0},{"id":"2575187214","title":"何氏眼科（301103）披露2025年限制性股票激励计划内幕信息知情人买卖公司股票情况自查报告，10月14日股价下跌1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575187214","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575187214?lang=zh_cn&edition=full","pubTime":"2025-10-14 22:44","pubTimestamp":1760453059,"startTime":"0","endTime":"0","summary":"截至2025年10月14日收盘，何氏眼科报收于20.41元，较前一交易日下跌1.11%，最新总市值为32.25亿元。公司近日发布公告，披露关于2025年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告。公告显示，公司于2025年9月19日召开董事会审议通过相关议案，并于9月23日披露公告。经向中国证券登记结算有限责任公司深圳分公司查询，自查期间所有内幕信息知情人均不存在买卖公司股票的行为。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400065646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301103"],"gpt_icon":0},{"id":"2574908941","title":"股市必读：何氏眼科（301103）9月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2574908941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574908941?lang=zh_cn&edition=full","pubTime":"2025-10-09 05:33","pubTimestamp":1759959196,"startTime":"0","endTime":"0","summary":"截至2025年9月30日收盘，何氏眼科报收于20.73元，上涨0.68%，换手率0.98%，成交量1.55万手，成交额3225.82万元。董秘最新回复投资者： 贵司提供白内障的诊断与手术治疗等个性化诊疗服务，是否考虑过并购像爱博医疗这样产品型公司，整合上下游资源，提升业务能力？后续如有达到信息披露标准的进展，公司将严格按照相关法律法规的要求及时履行信息披露义务。当日关注点来自交易信息汇总：9月30日主力资金净流出4.83万元，占总成交额0.15%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900001546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301103","BK0236"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765960546390,"stockEarnings":[{"period":"1week","weight":-0.0435},{"period":"1month","weight":-0.1413},{"period":"3month","weight":-0.1199},{"period":"6month","weight":-0.0868},{"period":"1year","weight":-0.1828},{"period":"ytd","weight":-0.0414}],"compareEarnings":[{"period":"1week","weight":-0.0217},{"period":"1month","weight":-0.0415},{"period":"3month","weight":-0.0133},{"period":"6month","weight":0.1376},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.1411}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"辽宁何氏眼科医院集团股份有限公司","boardCode":"AI0083","boardName":"卫生","stockholders":"9888人(较上一季度减少8.55%)","perCapita":"12301股","listingDate":"2022-03-22","address":"辽宁省沈阳市浑南区天赐街5-1号(607)","registeredCapital":"15802万元","survey":"　　辽宁何氏眼科医院集团股份有限公司的主营业务是向眼病患者提供眼科专科诊疗服务和视光服务。公司的主要产品是眼科专科诊疗服务和视光服务。","listedPrice":42.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"何氏眼科(301103)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供何氏眼科(301103)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"何氏眼科,301103,何氏眼科股票,何氏眼科股票老虎,何氏眼科股票老虎国际,何氏眼科行情,何氏眼科股票行情,何氏眼科股价,何氏眼科股市,何氏眼科股票价格,何氏眼科股票交易,何氏眼科股票购买,何氏眼科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"何氏眼科(301103)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供何氏眼科(301103)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}